Zuellig Pharma and Institut AllergoSan Establish 10-Year Alliance to Launch OMNi-BiOTiC® Probiotics in Key Asian Markets
Friday, July 19, 2024
Zuellig Pharma, a prominent healthcare solutions provider in Asia, has entered into a 10-year partnership with Institut AllergoSan, an Austrian company known for its natural-based products like probiotics, plant extracts, and minerals.
This collaboration will enable Zuellig Pharma to support the launch of OMNi-BiOTiC®, a leading probiotic brand from Institut AllergoSan, across major Asian markets. Zuellig Pharma will manage product registration, sales, marketing, and distribution as part of this partnership.
John Graham, Group CEO of Zuellig Pharma, emphasized, "Our consumer healthcare segment is expected to drive substantial growth, and this partnership represents a key advancement in our strategy to offer innovative healthcare solutions in Asia. Given the expanding probiotics market in the region, our commercial expertise through ZP Therapeutics will help address the growing demand for gut health products. Our joint efforts with Institut AllergoSan will enhance consumer wellness and support our mission to improve healthcare accessibility."
Anita Frauwallner, founder and CEO of Institut AllergoSan, noted, "We are focused on helping consumers achieve better health with our clinically supported probiotic supplements. OMNi-BiOTiC® is a top probiotic brand in German-speaking Europe, and we look forward to working with Zuellig Pharma to bring these products to more people in Asia."
Zuellig Pharma plans to introduce OMNi-BiOTiC® in Indonesia, the Philippines, and Taiwan in 2025, with plans to expand to additional markets in the future.
Source: zuelligpharma.com
